Skip to main content
Fig. 1 | EJNMMI Research

Fig. 1

From: Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer

Fig. 1

Image comparison of PET using [68Ga]Ga-PSMA-11 (left) and [18F]F-DCFPyL (right). PET images of patient no. 4 (lesions 6–12) are shown. Both PET with [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL show evidence of local recurrence and extensive iliac and retroperitoneal lymph node metastases, as shown in the maximum intensity projection images (top row). The coronary fusion images (bottom row) show the bi-iliac and retroperitoneal lymph node metastases as expected, while the local recurrence is outside the imaged plane. Visual impression of tracer distribution confirms the statistically suspected comparability of tumour-to-liver ratios and tumour-to-mediastinum ratios between PET using [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL. Furthermore, the well-known strengths of 18F-labelled PSMA tracers are apparent in the noticeable reduction in background noise and superior detectability of smaller lesions (green arrow) in the images from [18F]F-DCFPyL PET

Back to article page